Sign In
Buy RVVTF
$0.0190
+0.0010 (+5.56%)
At Close: Jul 31, 2026
Revive Therapeutics Approved to Trade on the OTCQB Market
03:09pm, Friday, 25'th Jun 2021
TORONTO, June 25, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the researc
Revive Therapeutics collaborates with University of Health Sciences Antigua to pioneer clinical development of psychedelics
10:00am, Thursday, 17'th Jun 2021
Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) (FRA:31R) is partnering with the University of Health Sciences Antigua (UHSA) to collaborate on utilizing the company's novel psychedelic-assisted the
Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics
08:05am, Thursday, 17'th Jun 2021
TORONTO, June 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the researc
Revive To Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
05:00pm, Monday, 14'th Jun 2021
TORONTO, June 14, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the researc
Revive Therapeutics partners with India-based specialty pharma Supriya Lifescience to advance Bucillamine to treat coronavirus
10:05am, Tuesday, 08'th Jun 2021
Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) (FRA:31R) says it has moved its global commercialization plans for Bucillamine to treat coronavirus (COVID-19) a step further by partnering with India
Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India
08:38am, Tuesday, 08'th Jun 2021
TORONTO, June 08, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the researc
Revive Therapeutics inks feasibility deal with Lohmann Therapie-Systeme to produce an oral psilocybin thin film strip
11:25am, Monday, 17'th May 2021
Revive Therapeutics Ltd (CSE:RVV) (OTC:RVVTF) (FRA:31R) has entered into a feasibility agreement with LTS Lohmann Therapie-Systeme AG to develop and manufacture a proprietary oral psilocybin thin film
Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip
09:24am, Monday, 17'th May 2021
TORONTO, May 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research
Revive Therapeutics partners with the University of California to study Bucillamine for treating severe COVID-19
03:32pm, Monday, 03'rd May 2021
Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) announced it has entered into a sponsored research agreement with the University of California, San Francisco (UCSF), to explore using the drug Buci
Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19
09:15am, Monday, 03'rd May 2021
TORONTO, May 03, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research
Revive Therapeutics Ltd. (CSE:RVV) (OTCMKTS:RVVTF) said it has filed an application with the US Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for Psilocybin to treat mode
Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury
09:17am, Tuesday, 27'th Apr 2021
TORONTO, April 27, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and developme
Revive Therapeutics files US provisional patent application for oral thin-film psilocybin product following research study
09:32am, Thursday, 22'nd Apr 2021
Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) (FRA:31R) announced the filing of a provisional patent application with the US Patent and Trademark Office (USPTO) for an oral thin-film (OTF) deliver
Revive Therapeutics has repurposed gout drug to fight coronavirus and is pushing into psychedelic medicine
07:03am, Thursday, 22'nd Apr 2021
Specialty life sciences company focused on developing drugs for rare disorders and infectious diseases Advancing clinical development of gout drug Bucillamine for infectious diseases, including COVID-
Revive Reschedules Annual and Special Meeting and Provides Dial-In Information
06:00pm, Thursday, 15'th Apr 2021
TORONTO, April 15, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and developme
